Literature DB >> 21465492

Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.

Daphne Hompes1, Henk Boot, Harm van Tinteren, Victor Verwaal.   

Abstract

BACKGROUND AND OBJECTIVES: For unresectable peritoneal carcinomatosis (PC) median overall survival (OS) is 5-6 months. This article analyzes patients with PC from colorectal cancer (CRC) uneligible for debulking and hyperthermic intra-peritoneal chemotherapy, describing patient- and tumor-related factors possibly affecting survival. PATIENTS AND METHODS: From 2005 to 2009, 43 patients presented with unresectable PC from CRC: male/female ratio was 29/14, median age was 57.1 years (range 34.8-76.8). "Unresectability" was defined as: six to seven abdominal regions affected by PC, involvement of mesentery or small bowel in the PC, presence of liver metastases, retroperitoneal lymph nodes, vascular invasion, and/or neural invasion.
RESULTS: Median time interval between diagnosis of the primary tumor and diagnosis of PC was 7.2 months (range 0.0-102.3). Primary tumors were right-sided in >50% and had been previously resected in >58%, 74.4% of PC occurred synchronously. Ascites was present at primary diagnosis in 37.2%. In 70% of cases, six to seven abdominal regions were affected and in 58.1% PC involved small bowel/mesentery. Systemic disease was present in 16.3%. In 18.6% of patients, a palliative diversion or ostomy was constructed. Median OS was 6.3 months (range 0.4-33.1). Thirty-one patients (72.1%) received palliative chemotherapy. Median OS was 9.3 months (range 0.9-33.1) with versus 3.1 months (range 0.4-6.5) without chemotherapy (P = 0.000), with less favorable patient and tumor characteristics in the latter group. No other factors clearly influenced OS.
CONCLUSION: Palliative chemotherapy results in better OS, but this is probably attributable to factors influencing the patient's general condition.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465492     DOI: 10.1002/jso.21937

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?

Authors:  Cem Terzi; Naciye Cigdem Arslan; Aras Emre Canda
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 2.  Outcome following incomplete surgical cytoreduction combined with intraperitoneal chemotherapy for colorectal peritoneal metastases.

Authors:  Roisin Mary Heaney; Conor Shields; Jurgen Mulsow
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

3.  Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.

Authors:  Nadine Leonie de Boer; Alexandra R M Brandt-Kerkhof; Eva V E Madsen; Marjolein Diepeveen; Esther van Meerten; Ruben A G van Eerden; Femke M de Man; Rachida Bouamar; Stijn L W Koolen; Ignace H J T de Hingh; Checca Bakkers; Koen P Rovers; Geert-Jan M Creemers; Maarten J Deenen; Onno W Kranenburg; Alexander Constantinides; Ron H J Mathijssen; Cornelis Verhoef; Jacobus W A Burger
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

4.  Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Anne Peen Rodt; Rebekka Oxenvad Svarrer; Lene Hjerrild Iversen
Journal:  World J Surg Oncol       Date:  2013-09-16       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.